Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient StoryRead more →

Stage II BRCA1 Breast Cancer: Joy's Survivor Story

Patient Info: Joy R., Female | Stage II

Biomarkers: BRCA1 mutation

As of June 2026, Joy had no evidence of disease after chemotherapy, double mastectomy, and hysterectomy for Stage II breast cancer with a BRCA1 mutation, and had moved from 3-month to 6-month oncology monitoring.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Stage II Invasive Ductal Carcinoma: Monica's Survivor Story

Patient Info: Monica, Female, Under 40 | Stage II

As of June 2026, Monica described survivorship after treatment for Stage IIB breast cancer and a separate undifferentiated pleomorphic sarcoma, with lasting neuropathy, bone pain, reconstruction complications, and grief around fertility.

The Patient StoryRead more →

BRCA2 Breast Cancer: Erika's Patient Story

Patient Info: Erika, Female, Under 40

Biomarkers: BRCA2 mutation

As of June 2026, Erika had no cancer diagnosis after a BRCA2-positive result and preventive double mastectomy with implant reconstruction, with ongoing hereditary-risk surveillance.

The Patient StoryRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tina's Patient Story

Patient Info: Tina, Female, Under 40 | Stage III

Biomarkers: ER-positive

As of June 2026, Tina was in survivorship after double mastectomy, AC-T chemotherapy, radiation, and ongoing hormone therapy with daily tamoxifen and Zoladex every 3 months.

The Patient StoryRead more →

Amy’s Stage 4 Hormone-Positive Lobular Breast Cancer Story

Patient Info: Amy, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: Spine; pelvis

Amy was living with de novo stage 4 lobular breast cancer involving the spine and pelvis and remained active in rural-patient advocacy.

Lobular Breast Cancer AllianceRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

Stage IV BRCA Breast Cancer: Maralee's Survivor Story

Patient Info: Maralee, Female, Under 40 | Stage IV

Biomarkers: BRCA mutation

Metastatic Site: Brain

As of May 2026, Maralee had no evidence of active disease after prior Stage IV breast cancer with brain metastasis, had stopped the PARP inhibitor after 2 years, remained without brain recurrence long enough to pursue pregnancy, and gave birth to a second daughter.

Cleveland ClinicRead more →

Stage ypT1aN0 triple-negative breast cancer with familial BRCA1 and OBSCN deletions

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative breast cancer; HER2 1+/negative; Ki-67 20%+. Familial testing showed BRCA1 and OBSCN deletions.

She underwent modified radical mastectomy with sentinel lymph node dissection and continued postoperative follow-up, with the main clinical emphasis on familial BRCA1/OBSCN genetic susceptibility.

PubMed CentralRead more →

Stage I luminal A invasive ductal breast cancer with post-treatment cognitive symptoms

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER 100% positive; PR 95% positive; HER2 score 0 / HER2-negative; Ki-67 10%; P63 negative

As of April 2026, the case focused on survivorship after Stage I luminal A breast cancer treatment, with cognitive complaints after chemotherapy and improved MoCA and depression scores after 12 sessions of tDCS; brain metastases had been ruled out.

PubMed CentralRead more →

Stage II Breast Cancer: Jenna's Patient Story

Patient Info: Jenna, Female, Under 40 | Stage II

Biomarkers: Hormone receptor-positive; HER2-negative; BRCA inherited gene mutations negative

As of April 2026, Jenna had completed pregnancy-associated chemotherapy and double mastectomy for Stage II HR-positive, HER2-negative breast cancer with 1 involved lymph node, did not need radiation, and was on hormone therapy for 10 years.

Breast Cancer: Muriel's Patient Story

Patient Info: Muriel, Female

As of 16 April 2026, Muriel was in the antihormonal-therapy phase, living largely symptom-free after breast surgery and chemotherapy, and supporting other people with cancer as a peer counselor.

Stage IV Breast Cancer: Erica's Patient Story

Patient Info: Erica, Female, 40s | Stage IV

Biomarkers: Hormone-positive; HER2-negative

Metastatic Site: Bone — ribs, sternum, spine, femur/right hip, shoulder…

Living with stable Stage IV hormone-positive, HER2-negative metastatic breast cancer involving multiple bones, currently managed with monthly hormone-suppressant injections and monitoring.

The Patient StoryRead more →

Invasive Lobular Carcinoma: Liz's Survivor Story

Patient Info: Liz O’Riordan, Female, 40s

Technically cancer-free after 2 local recurrences, with no metastatic disease stated, while continuing lifelong monthly injection treatment to reduce the risk of metastatic disease and living with scanxiety.

The Patient StoryRead more →

Triple-Negative Breast Cancer: Jes's Survivor Story

Patient Info: Jes, Female

Biomarkers: ER-negative; PR-negative; HER2-negative

No evidence of disease after chemotherapy/immunotherapy and bilateral mastectomy; no positive lymph nodes were found, chemotherapy cleared the cancer, and radiation was not needed, though she continued to experience long-term treatment effects.

The Patient StoryRead more →

Hormone receptor-positive high-grade encapsulated papillary breast carcinoma with limited invasion

Patient Info: Anonymized, Female, 40s

Biomarkers: ER/PR-positive, HER2-negative breast cancer; Ki-67 high in papillary/high-grade invasive areas; sentinel lymph nodes negative.

After mastectomy, sentinel-node evaluation, S-1, and endocrine therapy, she remained disease-free and in good health under regular follow-up.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Marina's Survivor Story

Patient Info: Marina, Female, Under 40

Biomarkers: BRCA1 mutation; triple-negative breast cancer

Triple-negative breast cancer survivor with a BRCA1 mutation who completed treatment after an initial diagnosis and a second diagnosis at the 5-year mark; no formal stage or metastatic disease was stated in the available source text.

The Patient StoryRead more →

Breast cancer treated separately from concurrent diffuse large B-cell lymphoma

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-positive

Follow-up after mastectomy showed no local recurrence of the breast cancer.

PubMed CentralRead more →

Metastatic invasive lobular breast cancer with stomach, ovarian, peritoneal, rectal, and jejunal spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Primary tumor and gastric metastasis were ER/PR positive and HER2 negative; GATA3 supported breast origin in the metastasis.

Metastatic Site: stomach; ovaries; peritoneum; rectum; jejunum

During 2025, she remained under active oncologic management for metastatic invasive lobular breast cancer with gastrointestinal, ovarian, peritoneal, rectal, and jejunal involvement.

PubMed CentralRead more →

ER-positive/HER2-positive breast cancer with rare paranasal sinus and skull metastasis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and paranasal sinus metastasis were ER positive, PR negative, HER2 positive; GATA3 supported breast origin in metastasis.

Metastatic Site: left frontal sinus; ethmoid air cells; posterior…

The paranasal sinus/skull metastasis did not respond to palliative radiotherapy; her condition deteriorated and she died 2 years after her initial presentation to the treating facility.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient StoryRead more →

Invasive Lobular Carcinoma: Louise's Survivor Story

Patient Info: Louise Butcher, Female

As of February 2026, Louise Butcher was living after lobular breast cancer, raising awareness about going flat, body image, and running after bilateral mastectomy.